The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?24/7 Wall Street • 08/27/26
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of strokePRNewsWire • 08/27/26
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patientsReuters • 08/25/26
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetesPRNewsWire • 08/25/26
Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.The Motley Fool • 08/24/26
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infantsPRNewsWire • 08/20/26
Here's How Abbott's Medical Devices Arm Acts as a Growth CatalystZacks Investment Research • 08/19/26
Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade)Seeking Alpha • 08/19/26
Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-TermSeeking Alpha • 08/19/26
Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcarePRNewsWire • 08/17/26
What's Backing Abbott's Established Pharmaceuticals Division GrowthZacks Investment Research • 08/13/26
Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AIPRNewsWire • 08/11/26
Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?Zacks Investment Research • 08/10/26
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/07/26
Here's How ABT Broadens Diagnostics Growth Base With Oncology ExpansionZacks Investment Research • 08/07/26
Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant24/7 Wall Street • 08/03/26
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 08/02/26